Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 17.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,490,064 shares of the company's stock after acquiring an additional 507,398 shares during the period. Pictet Asset Management Holding SA owned about 3.46% of Day One Biopharmaceuticals worth $44,219,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of DAWN. R Squared Ltd purchased a new stake in Day One Biopharmaceuticals during the 4th quarter worth about $31,000. E Fund Management Co. Ltd. acquired a new position in shares of Day One Biopharmaceuticals during the fourth quarter worth about $143,000. KLP Kapitalforvaltning AS acquired a new position in shares of Day One Biopharmaceuticals during the fourth quarter worth about $150,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Day One Biopharmaceuticals during the third quarter worth approximately $174,000. Finally, XTX Topco Ltd acquired a new stake in Day One Biopharmaceuticals in the third quarter valued at approximately $178,000. Hedge funds and other institutional investors own 87.95% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on DAWN. Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. dropped their target price on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Wedbush reaffirmed an "outperform" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. HC Wainwright reissued a "buy" rating and set a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of "Buy" and a consensus target price of $32.29.

Remove Ads

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the transaction, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This represents a 10.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 4,370 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the sale, the chief financial officer now directly owns 252,638 shares in the company, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,064 shares of company stock worth $251,925. Company insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Stock Down 6.4 %

DAWN traded down $0.49 during trading on Friday, hitting $7.22. 934,681 shares of the stock were exchanged, compared to its average volume of 1,099,661. Day One Biopharmaceuticals, Inc. has a 1-year low of $7.07 and a 1-year high of $18.07. The stock has a fifty day moving average price of $10.13 and a two-hundred day moving average price of $12.40. The firm has a market capitalization of $731.78 million, a P/E ratio of -7.01 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million. Analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.